(1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione | 766529-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione
• 英文别名: 3-O-(tert-butyldimethylsilyl)-4-oxoquinic acid 1,5-lactone；(1R,3R,5R)-3-[tert-butyl(dimethyl)silyl]oxy-1-hydroxy-6-oxabicyclo[3.2.1]octane-4,7-dione
• CAS: 766529-94-6
• 化学式: C₁₃H₂₂O₅Si
• 分子量: 286.4
• InChiKey: HLNBATPMBKHNSN-JRKPZEMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 在 吡啶 、 2,6-二甲基吡啶 、 sodium tetrahydroborate 、 sodium periodate 、 正丁基锂 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 为溶剂， 生成 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate
  参考文献：
  名称：

  Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects

  摘要：

  We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3 alpha S,7 alpha S)-1-((R)-1-((S)-3-hydroxy-2,3-dimethylbutoxy)ethyl)-7 alpha-methyldihydro-1H-inden-4(2H,5H,6H,7H,7 alpha H)-ylidene) ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation of a-ring phenylphosphine oxide 11, followed by Wittig-Horner coupling of 11 with the protected 25-hydroxy Grundmann's ketone 22 generated the precursor 12. Deprotection of the TBDMS groups of 12 produced the target compound VS-105. The biological profiles of VS-105 were evaluated using in vitro assays (VDR receptor binding, VDR reporter gene and HL-60 differentiation) in comparison to calcitriol (the endogenous hormone) or paricalcitol. Furthermore, the PTH suppressing potency and hypercalcemic side effects of VS-105 were evaluated in the 5/6 nephrectomized uremic rats in comparison to paricalcitol. Combining various changes at 20-epi, 22-oxa, 24-methyl, and 2-methylene yielded VS-105 that not only is highly potent in inducing functional responses in vitro, but also effectively suppresses PTH in a dose range that does not affect serum calcium in the 5/6 nephrectomized uremic rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.076
• 作为产物：
  描述：

  1,5-quinide 在 咪唑 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.5h， 生成 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione
  参考文献：
  名称：

  新的具有高肠活性的2-亚烷基1alpha，25-二羟基-19-诺维他命D3类似物：2-（3'-烷氧基亚丙基）和2-（3'-羟基亚丙基）衍生物的合成和生物学评估。

  摘要：

  在寻找具有潜在治疗价值的新型维生素D化合物，1α，25-二羟基-2-（3'-羟丙叉基）-19-正维生素D（3）的E-和Z-异构体及其衍生物有效地制备了在C-2具有3'-（甲氧基甲氧基）亚丙基取代基的前一化合物。所有维生素均以收敛合成方式获得，从（-）-奎尼酸和受保护的25-羟基Grundmann酮开始。将奎宁酸转化为酮内酯11，并通过Wittig反应连接一个取代的羟丙基亚基，生成成对的异构体化合物12、13和14、15。然后，将这些烯烃产物转化为氧化膦32-34，将其氧化为Lythgoe型Wittig-Horner与C，D片段35a和35b耦合。还详细说明了另一种方法，包括砜39a和39b与环己酮衍生物23的朱莉娅偶联。所有合成维生素与全长大鼠重组维生素D受体（VDR）的结合与1alpha相似或在1log内，25（OH）（2）D（3）。体内试验表明，E系列（5a，6a，6b）中所有类似物的钙化活性均明显高于天然激素。

  DOI：

  10.1021/jm051082a

文献信息

• [EN] VITAMIN D RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE LA VITAMINE D ET UTILISATIONS CORRESPONDANTES
  申请人：VIDASYM LLC

  公开号：WO2010120698A1

  公开（公告）日：2010-10-21

  Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

  揭示的是化合物Formula (I)，其中R1、R2、R3、R4、R5、R6、X和a在此处定义，或其药用可接受盐。还揭示了一种包含Formula (I)的化合物或其盐的制药组合物，以及一种治疗受益于调节维生素D受体的疾病的方法，如骨骼疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫障碍、左心室肥厚、增殖性疾病、蛋白尿、肾脏疾病和血栓形成。
• Vitamin D analogs for obesity prevention and treatment
  申请人：DeLuca F. Hector

  公开号：US20050119242A1

  公开（公告）日：2005-06-02

  Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D 3 or 1α,25-dihydroxyvitamin D 2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R 1 , R 2 , and R 3 have the values described herein.

  治疗和预防肥胖的方法，抑制脂肪细胞分化，抑制增加的SCD-1基因转录，和/或减少受试者体脂肪的方法包括向需要的受试者施用至少一种1α,25-二羟基维生素D3或1α,25-二羟基维生素D2的类似物或包含这种类似物的药物组合物。该类似物可以是19-去甲基维生素D类似物，如式IA的化合物，式IB的化合物，或其中的混合物，其中变量R1、R2和R3具有此处描述的值。
• 19-Nor-Vitamin D Analogs with 1,2 or 3,2 Heterocyclic Ring
  申请人：DeLuca Hector F.

  公开号：US20070238712A1

  公开（公告）日：2007-10-11

  19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis, osteomalacia, osteopenia, renal osteodystrophy and hypoparathyroidism.

  描述了具有额外杂环连接模拟物A环的3β-氧和碳-2或1α-氧和碳-2的19-去氢维生素D类似物，以及其药用途。这些化合物在骨骼的活动性中表现出显著活性，使它们成为治疗或预防骨质疏松症、骨软化症、骨质疏松、肾性骨病和甲状旁腺功能减退症的治疗药物。
• Novel and Efficient Syntheses of (−)-Methyl 4-<i>e</i><i>pi</i>-Shikimate and 4,5-Epoxy-Quinic and -Shikimic Acid Derivatives as Key Precursors to Prepare New Analogues
  作者：Laura Sánchez-Abella、Susana Fernández、Nuria Armesto、Miguel Ferrero、Vicente Gotor

  DOI：10.1021/jo0606249

  日期：2006.7.1

  We have developed simple methods that provide a rapid entry into the synthesis of a series of quinate and shikimate analogues, including (−)-methyl 4-epi-shikimate and the 4,5-epoxy analogues of the parent acids. Epoxy derivatives of quinic and shikimic acids were converted into methyl scyllo-quinate and (+)-methyl 3-epi-shikimate, respectively, by processes involving a regio- and stereoselective epoxide

  我们已经开发出简单的方法，这些方法可快速进入一系列奎宁酸盐和sh草酸盐类似物的合成，包括（-）-4- Epi -shikimate的甲基和母体酸的4,5-环氧类似物。的奎尼和莽草酸环氧衍生物转化成甲基鲨-quinate和（+） - 3-外延分别-shikimate，通过涉及区域选择性和立体选择性环氧化物开环过程。所描述的策略是通过短而高产的反应序列进行的。
• The Total Synthesis of (+)-Dragmacidin F
  作者：Neil K. Garg、Daniel D. Caspi、Brian M. Stoltz

  DOI：10.1021/ja046695b

  日期：2004.8.1

  The first total synthesis of (+)-dragmacidin F has been accomplished, establishing the absolute configuration of this biologically important, antiviral marine alkaloid. The convergent route described features a palladium-mediated oxidative pyrrole carbocylization reaction to construct the [3.3.1] bicycle, as well as a highly selective Suzuki coupling to build the carbon skeleton of the natural product

  (+)-dragmacidin F 的首次全合成已经完成，确立了这种具有重要生物学意义的抗病毒海洋生物碱的绝对构型。所描述的收敛路线具有钯介导的氧化吡咯碳酰化反应以构建 [3.3.1] 自行车，以及高选择性 Suzuki 偶联以构建天然产物的碳骨架。后期 Neber 重排允许轻松安装氨基咪唑部分以提供 (+)-dragmacidin F。